Lead Sponsor

University of Oslo School of Pharmacy

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Renal transplant recipients with stable renal function (plasma creatinine \< 200 µmol/L)
•Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion
•\> 18 years of age
•Male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs
•Signed informed consent

•Patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not
•Patients with a known hypersensitivity to rosuvastatin
•Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study \[e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs\]
•Pregnant or nursing mothers